- •Uveitis
- •Foreword
- •Preface
- •Dedication
- •Acknowledgments
- •Elements of the Immune System and Concepts of Intraocular Inflammatory Disease Pathogenesis
- •Elements of the immune system
- •Macrophages/monocytes
- •Dendritic cells
- •T cells
- •Major subsets of T cells
- •Cytokines
- •T-cell subsets
- •T-regulatory cells
- •T-cell receptor
- •Chemokines
- •Thymic expression and central immune tolerance
- •B cells
- •Classes of Immunoglobulin
- •Other cells
- •Mast Cells
- •Eosinophils
- •Neutrophils
- •Resident Ocular Cells
- •Complement system
- •Cellular interactions: hypersensitivity reactions
- •Classic immune hypersensitivity reactions
- •Type I
- •Type II
- •Type III
- •Type IV
- •Type V
- •Concepts of disease pathogenesis
- •Immune characteristics of the eye
- •Absence of lymphatic drainage
- •Intraocular microenvironment
- •Anterior Chamber-Associated Immune Deviation (ACAID)
- •Fas-Fas Ligand Interactions and Programmed Cell Death (Apoptosis)
- •Resident Ocular Cells and Immune System
- •Cytokines and Chemokines and the Eye
- •Oral Tolerance
- •Choroidal circulation and anatomy
- •Retina
- •Immunogenetics
- •Class I antigens
- •Class II and class III antigens
- •Histocompatibility lymphocyte antigens
- •Single-nucleotide polymorphisms (SNPs)
- •Epigenetics
- •Immune complex-mediated disease
- •Gene expression profiling
- •Tissue damage in the eye
- •T-cell responses and autoimmunity
- •T-cell receptor and the expression of disease
- •Ocular autoimmunity
- •Uveitogenic antigens
- •Retinal S-Antigen (Arrestin)
- •Interphotoreceptor Retinoid-Binding Protein
- •Recoverin
- •Bovine Melanin Protein
- •Rhodopsin
- •Phosducin
- •Tyrosinase
- •Other Antigens
- •Endotoxin and Other Bacterial Antigens
- •Importance of Antigen Studies
- •Cell adhesion molecules and their role in lymphocyte homing and in disease
- •Immune responses to invading viruses and parasites
- •Suggested Readings
- •References
- •Medical History in the Patient with Uveitis
- •References
- •Sample Uveitis Questionnaire
- •FAMILY HISTORY
- •SOCIAL HISTORY
- •PERSONAL MEDICAL HISTORY
- •MEDICAL HISTORY
- •Examination of the Patient with Uveitis
- •Visual acuity
- •External examination
- •Pupils and extraocular muscles
- •Intraocular pressure measurement
- •Slit-lamp biomicroscopy
- •Conjunctiva
- •Cornea
- •Keratic Precipitates
- •Other Corneal Findings
- •Anterior chamber
- •Iris
- •Anterior chamber angle
- •Lens
- •Vitreous
- •Retina and choroid
- •Optic nerve
- •References
- •Development of a Differential Diagnosis
- •Forming a differential diagnosis
- •Classifying uveitis
- •Is the disease acute or chronic?
- •Is the inflammation granulomatous or nongranulomatous?
- •Is the disease unilateral or bilateral?
- •Where is the inflammation located in the eye?
- •What are the demographics of the patient?
- •What associated symptoms does the patient have?
- •What associated signs are present on physical examination?
- •What is the time course of the disease and response to previous therapy?
- •Case 4-1
- •Case 4-2
- •References
- •Diagnostic Testing
- •Pretest likelihood of disease
- •Receiver operating characteristic (ROC) curve
- •Diagnostic tests for uveitis
- •Laboratory tests
- •Image analysis
- •Skin testing
- •Tissue samples
- •Ancillary ophthalmic tests
- •Electrophysiology
- •Laser interferometry
- •Fluorescein angiography
- •Indocyanine green
- •Laser flare photometry
- •Optical coherence tomography
- •High-frequency ultrasound biomicroscopy and multifrequency ultrasound
- •Fundus autofluorescence
- •Other diagnostic tests
- •Polymerase chain reaction (PCR)
- •Rapid tests for herpes simplex and herpes zoster
- •Bone mineral density studies
- •Genetic testing for steroid-induced glaucoma
- •Neurologic tests
- •References
- •Evidence-Based Medicine in Uveitis
- •Study design
- •Clinical trials in uveitis
- •References
- •Philosophy, Goals, and Approaches to Medical Therapy
- •Goals and philosophy
- •Pain, photophobia, and discomfort
- •Degree and location of inflammatory disease
- •Evaluation of visual acuity and prospect of reversibility
- •Follow-up procedures and standardization of observations
- •General health and age of patient
- •Patient reliability, preferences, and understanding
- •Nonsurgical therapeutic options
- •Corticosteroids
- •Mode of Action
- •Preparations, Dosage Schedules, and Complications
- •Ozurdex.
- •Secondary Effects
- •Cytotoxic agents
- •Alkylating agents
- •Mode of Action
- •Indications and Dosages
- •Secondary Effects
- •Antimetabolites
- •Azathioprine
- •Mode of Action
- •Indications and Dosages
- •Secondary Effects
- •Mycophenolate mofetil
- •Methotrexate
- •Mode of Action
- •Indications and Dosages
- •Secondary Effects
- •Ciclosporin
- •Mode of Action
- •Dosages and Indications
- •Secondary Effects
- •Tacrolimus
- •Mode of Action
- •Indications and Dosages
- •Secondary Effects
- •Lx 211 (Voclosporin)
- •Rapamycin
- •Mode of Action
- •Indications and Dosages
- •Toxicity
- •Antibodies and monoclonal antibodies
- •Daclizumab
- •Etanercept
- •Infliximab (Remicade)
- •Adalimumab (Humira)
- •Efalizumab (Raptiva)
- •Rituximab (Rituxan)
- •Anakinra (Kineret)
- •Alemtuzumab (Campath-1H)
- •Abatacept (Orencia)
- •Intravenous immunoglobulin therapy
- •Oral tolerance
- •Interferon-α
- •Antiviral therapy
- •Aciclovir
- •Ganciclovir
- •Valaciclovir
- •Famciclovir
- •Foscarnet
- •Combined ganciclovir and foscarnet
- •Cidofovir
- •Fomivirsen
- •Colchicine
- •Mode of Action
- •Indications and Dosages
- •Secondary Effects
- •Mydriatic and cycloplegic agents
- •Antitoxoplasmosis therapy
- •Other therapeutic approaches
- •Immunostimulators
- •Plasmapheresis
- •Nonsteroidal antiinflammatory agents
- •References
- •Role of Surgery in the Patient with Uveitis
- •Considerations
- •Removal of band keratopathy
- •Corneal transplantation
- •Cataract surgery
- •Glaucoma surgery
- •Treatment of vitreoretinal disease
- •Laser treatment
- •Photodynamic therapy
- •Diagnostic surgery
- •Anterior chamber paracentesis
- •Chorioretinal biopsy
- •Subretinal surgery
- •Case 8-1
- •References
- •Bacterial and Fungal Diseases
- •Introduction
- •Leprosy
- •Clinical findings
- •Immunology and pathology
- •Therapy
- •Tuberculosis
- •Systemic disease
- •Ocular disease
- •Diagnosis
- •Therapy
- •Other bacterial infections
- •Brucellosis
- •Whipple’s disease
- •Treatment and prognosis
- •Chronic granulomatous disease
- •Fungal disease
- •Neuroretinitis
- •References
- •Spirochetal Diseases
- •Spirochetal infections and the eye
- •Spirochetes
- •Definition
- •Venereal treponemal diseases
- •Syphilis
- •Etiology and Epidemiology
- •Clinical Manifestations
- •Primary syphilis.
- •Secondary syphilis.
- •Latent syphilis.
- •Tertiary syphilis.
- •Benign tertiary syphilis.
- •Cardiovascular syphilis.
- •Neurosyphilis.
- •Congenital syphilis.
- •Ocular Manifestations
- •Diagnosis
- •Prognosis
- •Treatment
- •General recommendations.
- •Approach to Syphilis in Patients with AIDS
- •Nonvenereal treponematoses
- •Endemic syphilis
- •Etiology and Epidemiology
- •Clinical Manifestations
- •Ocular Manifestations
- •Diagnosis
- •Prognosis
- •Treatment
- •Yaws and pinta
- •Ocular Manifestations
- •Diagnosis
- •Prognosis
- •Treatment
- •Borrelia infection
- •Lyme disease
- •Etiology and Epidemiology
- •Clinical Manifestations
- •Ocular Manifestations
- •Diagnosis
- •Prognosis
- •Treatment
- •Relapsing fever
- •Etiology and Epidemiology
- •Clinical Manifestations
- •Ocular Manifestations
- •Diagnosis
- •Prognosis
- •Treatment
- •Leptospirosis
- •Etiology and Epidemiology
- •Clinical Manifestations
- •Ocular Manifestations
- •Weil’s disease
- •Diagnosis
- •Prognosis
- •Treatment
- •Case 10-1
- •References
- •Acquired Immunodeficiency Syndrome
- •Human immunodeficiency virus
- •Epidemiology
- •Diagnosis
- •HIV disease
- •HIV therapy
- •Ocular manifestations of HIV infection
- •Ocular infection
- •Cytomegalovirus retinitis
- •Progression
- •CMV retinitis in the era of highly active antiretroviral therapy
- •Treatment
- •Intravitreal ganciclovir implant
- •Current therapeutic approach to CMV retinitis in the era of HAART
- •Retinal detachment
- •Prognosis
- •Immune recovery uveitis
- •Herpes zoster
- •Pneumocystis jirovecii choroiditis
- •Mycobacterium avium-intracellulare choroiditis
- •Other diseases
- •Drug-related ocular inflammation
- •Case 11-1
- •Case 11-2
- •References
- •Acute retinal necrosis
- •Epidemiology
- •Clinical features
- •Etiology
- •Differential diagnosis
- •Therapy
- •Progressive outer retinal necrosis
- •Diagnosis
- •Differential diagnosis
- •Etiology
- •Therapy
- •Case 12-1
- •Case 12-2
- •References
- •Other Viral Diseases
- •Herpes simplex virus kerititis and keratouveitis
- •Pathogenesis
- •Diagnosis
- •Treatment
- •Herpes zoster ophthalmicus
- •Treatment
- •West Nile virus
- •Epidemiology
- •Diagnosis
- •Clinical description
- •Ophthalmic manifestations
- •Treatment
- •Prognosis
- •Other viral infections
- •Human T-lymphotropic virus type I
- •Case 13-1
- •References
- •Ocular Toxoplasmosis
- •Organism
- •Clinical manifestations
- •Systemic
- •Ocular
- •Decreased Vision
- •Loss of Vision
- •Effects in immunocompromised host
- •Histopathology and immune factors
- •Immune response
- •Inflammatory response
- •Methods of diagnosis
- •Pregnancy
- •Other methods
- •Congenital versus acquired disease
- •Therapy
- •Additional therapeutic approaches
- •Case 14-1
- •Case 14-2
- •Case 14-3
- •Case 14-4
- •References
- •Ocular Histoplasmosis
- •Systemic findings
- •Ocular appearance
- •‘Histo’ spots
- •Maculopathy
- •Peripapillary pigment changes
- •Clear vitreous
- •Etiology and immunology
- •Nonsurgical therapies
- •Laser therapy
- •Subretinal surgery
- •References
- •Toxocara canis
- •Ocular manifestations
- •Histopathology and immune factors
- •Enzyme-linked immunoabsorbent assay
- •Treatment
- •Case 16-1
- •References
- •Onchocerciasis and Other Parasitic Diseases
- •Onchocerciasis
- •Clinical appearance
- •Immune characteristics
- •Therapy
- •Giardiasis
- •Ophthalmomyiasis
- •Cysticercosis
- •Caterpillar hairs
- •Amebiasis
- •Diffuse unilateral subacute neuroretinitis (DUSN)
- •Malaria
- •Seasonal hyperacute panuveitis (SHAPU)
- •References
- •Postsurgical Uveitis
- •Acute bacterial endophthalmitis
- •Chronic bacterial endophthalmitis
- •Fungal endophthalmitis
- •Endogenous endophthalmitis
- •Lens-induced uveitis
- •Toxic anterior segment syndrome (TASS)
- •Laser-induced uveitis
- •Case 18-1
- •References
- •Anterior Uveitis
- •Epidemiology
- •Clinical description
- •Idiopathic anterior uveitis
- •Diagnostic workup
- •Treatment
- •HLA-B27–associated anterior uveitis
- •Epidemiology
- •Demographics and clinical findings
- •Etiology
- •HLA-B27–associated anterior uveitis with systemic disease
- •Ankylosing spondylitis
- •Etiology
- •Treatment
- •Reactive arthritis (Reiter’s syndrome)
- •Juvenile idiopathic arthritis
- •Diagnosis
- •Pathology
- •Differential diagnosis
- •Treatment and prognosis
- •Psoriatic arthropathy
- •Inflammatory bowel disease
- •Whipple’s disease
- •Disease associations
- •Fuchs’ heterochromic iridocyclitis
- •Etiology
- •Treatment and prognosis
- •Kawasaki disease
- •Tubulointerstitial nephritis and uveitis syndrome (TINU)
- •Pathogenesis
- •Glaucomatous cyclitic crisis
- •Schwartz syndrome
- •Anterior segment ischemia
- •Lens-induced uveitis
- •Anterior uveitis associated with AIDS
- •Other disease associations
- •References
- •Scleritis
- •Episcleritis
- •Scleritis
- •Disease associations
- •Other causes of scleritis
- •Diagnostic testing
- •Pathogenesis
- •Differential diagnosis
- •Treatment
- •References
- •Intermediate Uveitis
- •Epidemiology
- •Clinical manifestations
- •Prognosis
- •Differential diagnosis
- •Multiple sclerosis
- •Etiology
- •Treatment
- •Corticosteroids
- •Immunosuppressive agents
- •Surgery
- •Case 21-1
- •Case 21-2
- •References
- •Sarcoidosis
- •Epidemiology
- •Etiology
- •Clinical manifestations
- •Anterior uveitis
- •Posterior segment findings
- •Systemic involvement
- •Pathology
- •Diagnosis
- •Treatment
- •Case 22-1
- •References
- •Sympathetic Ophthalmia
- •Clinical appearance and prevalence
- •Classic presentation
- •Sequelae
- •Tests and immunologic characteristics
- •Dalen–fuchs nodules
- •Preservation of the choriocapillaris
- •Therapy
- •Corticosteroids
- •Immunosuppressive agents
- •Case 23-1
- •Case 23-2
- •References
- •Vogt–Koyanagi–Harada Syndrome
- •Clinical aspects
- •Systemic findings
- •Ocular findings
- •Course of disease
- •Laboratory tests, etiology, and histopathology
- •Antigen-specific and immune responses
- •Vogt–Koyanagi–Harada syndrome versus sympathetic ophthalmia
- •Therapy
- •Cataract extraction
- •Case 24-1
- •Case 24-2
- •References
- •Birdshot Retinochoroidopathy
- •Clinical manifestations
- •Ocular examination and ancillary clinical tests
- •Tests, histology and etiology
- •Therapy
- •Case 25-1
- •Case 25-2
- •References
- •Behçet’s Disease
- •Clinical manifestations
- •Oral aphthous ulcers
- •Skin lesions
- •Genital ulcers
- •Ocular disease
- •Retinal disease
- •Complications
- •Minor criteria
- •Arthritis
- •Vascular alterations
- •Neurologic involvement (neuro-Behçet’s disease)
- •Immunologic and histologic considerations
- •Role of T cells (but other cells count too!)
- •HLA typing and single nucleotide polymorphisms (SNPs)
- •Therapy
- •Systemic corticosteroids
- •Cytotoxic and antimetabolic agents
- •Colchicine
- •Interferon-α
- •Ciclosporin and tacrolimus (FK506)
- •Anti-TNF therapy (infliximab)
- •Other approaches
- •Case 26-1
- •Case 26-2
- •Case 26-3
- •References
- •Retinal Vasculitis
- •Clinical characteristics
- •Ocular vasculitic disorders without systemic disease
- •Eales’ disease
- •Idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN syndrome)
- •Frosted branch angiitis
- •Scleritis
- •Ocular vasculitic disorders with systemic disease
- •Systemic lupus erythematosus
- •Polyarteritis nodosa
- •Wegener’s granulomatosis
- •Whipple’s disease
- •Inflammatory bowel disease
- •Autoantibodies to Sjögren’s syndrome A antigen
- •Retinal vein occlusion
- •Relapsing polychondritis
- •Viral diseases
- •Multiple sclerosis
- •Tuberculosis
- •Rheumatoid arthritis
- •Kikuchi–Fujimoto disease
- •Susac syndrome
- •Sweet syndrome
- •References
- •Serpiginous Choroidopathy
- •Clinical features
- •Pathology
- •Etiology
- •Differential diagnosis
- •Therapy
- •Case 28-1
- •Case 28-2
- •Case 28-3
- •References
- •White-Dot Syndromes
- •Multiple evanescent white-dot syndrome
- •Clinical findings
- •Laboratory findings
- •Therapy
- •Multifocal choroiditis and panuveitis
- •Clinical findings
- •Punctate inner choroidopathy
- •Laboratory findings
- •Therapy
- •Acute retinal pigment epitheliitis
- •Clinical findings
- •Laboratory findings
- •Therapy
- •Acute posterior multifocal placoid pigment epitheliopathy
- •Clinical findings
- •Etiology
- •Therapy
- •Subretinal fibrosis and uveitis syndrome
- •Clinical findings
- •Laboratory findings
- •Therapy
- •Acute zonal occult outer retinopathy (AZOOR) and the azoor complex diseases
- •Case 29-1
- •Case 29-2
- •Case 29-3
- •References
- •Masquerade Syndromes
- •Intraocular lymphoma
- •Non-Hodgkin’s lymphoma of central nervous system
- •Diagnosis
- •Treatment
- •Systemic Non-Hodgkin’s lymphoma metastatic to eye
- •Lymphoid hyperplasia of uvea
- •Other malignant processes manifesting as uveitis
- •Paraneoplastic syndromes
- •Multiple sclerosis
- •Other nonmalignant conditions
- •References
- •Introduction
- •Age-related macular degeneration
- •Animal work
- •Animal laser model
- •Ccl2 and Ccr2 knockout model
- •Ccl2 and Cx3cr1 double knockout model
- •CEP induced AMD-like disease
- •Human data
- •Autoimmunity
- •Gene associations
- •Macrophages and other cells
- •Histopathology
- •The downregulatory immune environment
- •Should we consider immunotherapy?
- •Diabetic retinopathy
- •Diabetes and the immune process
- •Animal work
- •Human observations
- •Can we begin to think about immune therapy for diabetes and diabetic retinopathy?
- •Glaucoma
- •Autoantibodies and glaucoma
- •Cellular immunity and glaucoma
- •Can immune intervention help alter the course of glaucoma?
- •References
- •Index
|
5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
4 |
|
|
|
|
|
|
|
|
|
|
(10) |
> Photo c |
thickening |
|
|
|
|
|
|
|
|
|
|
|
||
3 |
|
|
|
|
|
|
|
(8) |
(3) |
(5) |
> Photo b but |
||
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
< or = c |
|||
|
|
|
|
|
|
|
|
|
|
|
|
||
Macular |
|
(2) |
(6) |
|
|
|
|
< or = b |
|||||
|
2 |
|
|
|
|
|
|
|
> Photo a but |
||||
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4) |
|
|
|
|
|
(1) (7) |
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
||||
|
1 |
(9) |
|
|
|
|
|
< or = Photo a |
|||||
|
0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
0 |
|
|
|
|
|
5 |
|
10 |
|
|||
|
|
|
|
|
|
|
|
|
|||||
Measured visual acuity (Logmar score)
Figure 5-5. Mean (±1 standard error) of 13 gradings of macular thickening for eyes with cystoid macular edema (11 because of uveitis, two because of diabetes). Simple linear regression showed significant relationship between mean thickening and actual visual acuity. (From Nussenblatt RB, Kaufman SC, Palestine AG, et al. Macular thickening and visual acuity. Ophthalmology 1987; 94: 1134–9.)
Ancillary ophthalmic tests
will provide new insight into the pathophysiology of a number of uveitic disorders.
Laser flare photometry
Although standardized schemes for assessing anterior chamber cells and flare have been described in the literature, grading differs tremendously between clinicians and even for the same grader over time. A laser device has been developed to assess flare in the anterior chamber of the eye and should standardize the grading of anterior chamber inflammation; objective grading of flare is extremely useful in determining response to therapy.49,50 Furthermore, it is difficult to detect the induced flare caused by small amounts of protein in the aqueous humor resulting from early breakdown of the blood–aqueous barrier. After cataract surgery, for example, it would be nice to predict which eyes were at risk of developing uveitis and cystoid macular edema. The laser flare photometer is more sensitive than the eye in detecting flare and may be useful in predicting which eyes are at risk for developing worsening inflammatory disease, and possibly identifying eyes that require more aggressive antiinflammatory therapy. In one study of 30 uveitis patients, outflow facility was significantly reduced in patients with elevated flare photometry results.51 An association between laser flare photometry values and complications of uveitis has also been reported.52 However, randomized clinical trials have not demonstrated that increasing therapy to decrease laser flare photometry values improves clinical outcomes compared to basing therapy on clinical assessment.53
A B
Figure 5-6. Proposed scheme as to why fluorescein leakage may appear to be same but macular thickening may have decreased, resulting in improvement in visual acuity. A, During an acute episode of uveitis, cystic spaces are filled with fluid and the macula is thickened. B, With therapy there is a reduction in macular thickening but the amount of leakage will appear to be the same if the angiogram is reviewed in standard fashion.
(From Nussenblatt RB, Kaufman SC, Palestine AG, et al. Macular thickening and visual acuity. Ophthalmology 1987; 94: 1134–9.)
choroidal blood flow, including choroidal neovascular membranes.41–44
ICG angiography has now been used to study patients with a number of uveitic conditions. In patients with serpiginous choroiditis, ICG angiography has demonstrated blockage of choroidal fluorescence in active areas of lesions with return of the normal choroidal fluorescence as the inflammation subsided.45 In addition, the chorioretinal lesions associated with birdshot choroiditis are often difficult to observe clinically or to document with fluorescein angiography. However, Krupsky and colleagues46 showed that ICG angiography was superior to fluorescein angiography in demonstrating these lesions that appeared as hypofluorescent areas, suggesting loss of the choriocapillaris. Herbort and colleagues47,48 have used ICG angiography to assess disease activity in several forms of uveitis, including VKH and Behçet’s disease. Researchers are also using ICG angiography to compare active and quiescent chorioretinal lesions in patients with uveitis, and it is hoped that this technique
Optical coherence tomography
Optical coherence tomography (OCT) allows the noninvasive assessment of retinal thickness. This technique may be useful in assessing retinal edema in patients with uveitis and response to therapy. In a recent study, Antcliff and associates54 compared OCT and fluorescein angiography in 58 patients with uveitis and suspected cystoid macular edema (CME). One hundred and eight eyes had similar results by both OCT and fluorescein angiography; 67 eyes had CME and 41 eyes had no CME. In 10 eyes subretinal fluid was detected by OCT but not by fluorescein angiography. Five of these eyes had CME detected by fluorescein angiography but not by OCT. Three other eyes had CME detected by fluorescein angiography but not by OCT. The authors concluded that OCT is as effective as fluorescein angiography for detecting CME but is superior for demonstrating axial distribution of fluid. Similar to fluorescein angiography, the accuracy of the measurements is affected by small pupil size and media opacity.
Since the last edition of this book there have been improvements in OCT technology and a number of new studies assessing the use in uveitis. OCT is useful for detecting macular edema and assessing response to therapy.55 Reductions in macular thickness in patients with uveitic CME can be detected on OCT within a week of corticosteroid therapy (Fig. 5-7). OCT may be useful in detecting retinal pathology in other forms of posterior uveitis.56 Finally, spectral-domain OCT may provide additional information and be useful in assessing uveitic eyes, especially when hazy media obscures clinical examination.57
67
- #28.03.202681.2 Mб0Ultrasonography of the Eye and Orbit 2nd edition_Coleman, Silverman, Lizzi_2006.pdb
- #
- #
- #
- #28.03.202621.35 Mб0Uveitis Fundamentals and Clinical Practice 4th edition_Nussenblatt, Whitcup_2010.chm
- #
- #
- #28.03.202627.87 Mб0Vaughan & Asbury's General Ophthalmology 17th edition_Riordan-Eva, Whitcher_2007.chm
- #
- #
- #
